|
|
||||||||
J Thorac Cardiovasc Surg 1998;115:660-670
© 1998 Mosby, Inc.
GENERAL THORACIC SURGERY |
From the Thoracic Service, Department of Surgery,a and the Biostatistics Service, Department of Epidemiology and Biostatistics,b Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Read at the Twenty-third Annual Meeting of The Western Thoracic Surgical Association, Napa, Calif., June 25-28, 1997.
Received for publication July 1, 1997; revisions requested Oct. 13, 1997; revisions received Nov. 14, 1997; accepted for publication Nov. 17, 1997. Address for reprints: Valerie W. Rusch, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.
Objectives: This study analyzed survival with respect to lymph node involvement to develop a new staging system for patients with esophageal cancer that accurately reflects prognosis.
Methods: The records of patients undergoing resection of primary esophageal cancer from 1989 to 1993 were reviewed. The data collected included patient age and sex, tumor histologic characteristics and location, the use of preoperative or postoperative radiation and chemotherapy, the type of resection, the depth of tumor invasion, the number and location of benign and malignant lymph nodes in the resected specimen, the disease status at last follow-up, and the first site of relapse. With an anatomically specific lymph node map, tumors designated in the current American Joint Committee on Cancer system as M1 because of extensive lymph node metastases were reclassified as N2, reserving the M1 category for visceral metastases. Survival was analyzed by the Kaplan-Meier method, and prognostic factors were assessed by log-rank and Cox regression analyses.
Results: There were 216 patients (159 men, 57 women) with a median age of 63.5 years. Adenocarcinoma of the distal esophagus or gastroesophageal junction was the most common tumor (127 patients, 59%) and Ivor Lewis esophagogastrectomy was the most frequently performed operation. Both lymph node location (N1 versus N2) and number (0 vs 1 to 3 vs 4 or more) significantly influenced survival.
Conclusions: A new staging system that adds an N2 M0 descriptor and reclassifies stage groupings reflects prognosis more accurately than does the current American Joint Committee on Cancer staging system. The number of positive lymph nodes is also an important stratification factor.
This article has been cited by other articles:
![]() |
K. Sillah, S. A. Pritchard, G. R. Watkins, J. McShane, C. M. West, R. Page, and I. M. Welch The degree of circumferential tumour involvement as a prognostic factor in oesophageal cancer Eur. J. Cardiothorac. Surg., August 1, 2009; 36(2): 368 - 373. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. Lee, J. L. Port, S. Paul, B. M. Stiles, and N. K. Altorki Predictors of long-term survival after resection of esophageal carcinoma with nonregional nodal metastases. Ann. Thorac. Surg., July 1, 2009; 88(1): 186 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Chen, Z. Wang, X.-y. Liu, and F.-y. Liu Adjuvant Radiotherapy After Modified Ivor-Lewis Esophagectomy: Can It Prevent Lymph Node Recurrence of the Mid-Thoracic Esophageal Carcinoma? Ann. Thorac. Surg., June 1, 2009; 87(6): 1697 - 1702. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Kim, H. Y. Kim, K. W. Lee, and M. S. Kim Multimodality Assessment of Esophageal Cancer: Preoperative Staging and Monitoring of Response to Therapy1 RadioGraphics, March 1, 2009; 29(2): 403 - 421. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Chen, Z. Wang, X.-y. Liu, M.-y. Zhang, and F.-y. Liu Clinical study of modified Ivor-Lewis esophagectomy plus adjuvant radiotherapy for local control of stage IIA squamous cell carcinoma in the mid-thoracic esophagus Eur. J. Cardiothorac. Surg., January 1, 2009; 35(1): 1 - 7. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Li, Q. Zhang, L. Xu, Y. Chen, Y. Wei, and G. Zhou Factors predictive of prognosis after esophagectomy for squamous cell cancer. J. Thorac. Cardiovasc. Surg., January 1, 2009; 137(1): 55 - 59. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tachibana, S. Kinugasa, N. Hirahara, and H. Yoshimura Lymph node classification of esophageal squamous cell carcinoma and adenocarcinoma. Eur. J. Cardiothorac. Surg., August 1, 2008; 34(2): 427 - 431. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Lee, S.-B. Kim, S.-I. Park, Y. H. Kim, J.-S. Ryu, H.-Y. Song, J. H. Shin, H. Y. Jung, G. H. Lee, K. D. Choi, et al. Capecitabine and Cisplatin Chemotherapy (XP) Alone or Sequentially Combined Chemoradiotherapy Containing XP Regimen in Patients with Three Different Settings of Stage IV Esophageal Cancer Jpn. J. Clin. Oncol., November 1, 2007; 37(11): 829 - 835. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Bruzzi, R. F. Munden, M. T. Truong, E. M. Marom, B. S. Sabloff, G. W. Gladish, R. B. Iyer, T.-S. Pan, H. A. Macapinlac, and J. J. Erasmus PET/CT of Esophageal Cancer: Its Role in Clinical Management RadioGraphics, November 1, 2007; 27(6): 1635 - 1652. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Hofstetter, A. M. Correa, N. Bekele, J. A. Ajani, A. Phan, R. R. Komaki, Z. Liao, D. Maru, T. T. Wu, R. J. Mehran, et al. Proposed Modification of Nodal Status in AJCC Esophageal Cancer Staging System Ann. Thorac. Surg., August 1, 2007; 84(2): 365 - 375. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Dhar, S. Hattori, Y. Tonomoto, T. Shimoda, H. Kato, M. Tachibana, K. Matsuura, Y. Mitsumoto, A. G. Little, and N. Nagasue Appraisal of a Revised Lymph Node Classification System for Esophageal Squamous Cell Cancer Ann. Thorac. Surg., April 1, 2007; 83(4): 1265 - 1272. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Kim, K. H. Lee, Y. H. Kim, S. W. Sung, S. Jheon, S.-k. Cho, and K. W. Lee Postoperative Imaging of Esophageal Cancer: What Chest Radiologists Need to Know RadioGraphics, March 1, 2007; 27(2): 409 - 429. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. P. Rizk, E. Venkatraman, M. S. Bains, B. Park, R. Flores, L. Tang, D. H. Ilson, B. D. Minsky, and V. W. Rusch American Joint Committee on Cancer Staging System Does Not Accurately Predict Survival in Patients Receiving Multimodality Therapy for Esophageal Adenocarcinoma J. Clin. Oncol., February 10, 2007; 25(5): 507 - 512. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Rizk, E. Venkatraman, B. Park, R. Flores, M. S. Bains, and V. Rusch The prognostic importance of the number of involved lymph nodes in esophageal cancer: Implications for revisions of the American Joint Committee on Cancer staging system J. Thorac. Cardiovasc. Surg., December 1, 2006; 132(6): 1374 - 1381. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Lagarde, F. J.W. ten Kate, J. B. Reitsma, O. R.C. Busch, and J. J. B. van Lanschot Prognostic Factors in Adenocarcinoma of the Esophagus or Gastroesophageal Junction J. Clin. Oncol., September 10, 2006; 24(26): 4347 - 4355. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Rizk, R. J. Downey, T. Akhurst, M. Gonen, M. S. Bains, S. Larson, and V. Rusch Preoperative 18[F]-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values Predict Survival After Esophageal Adenocarcinoma Resection Ann. Thorac. Surg., March 1, 2006; 81(3): 1076 - 1081. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lee, K.-E. Lee, Y.-H. Im, W. K. Kang, K. Park, K. Kim, and Y. M. Shim Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma Ann. Thorac. Surg., October 1, 2005; 80(4): 1170 - 1175. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Chirieac, S. G. Swisher, A. M. Correa, J. A. Ajani, R. R. Komaki, A. Rashid, S. R. Hamilton, and T.-T. Wu Signet-Ring Cell or Mucinous Histology after Preoperative Chemoradiation and Survival in Patients with Esophageal or Esophagogastric Junction Adenocarcinoma Clin. Cancer Res., March 15, 2005; 11(6): 2229 - 2236. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Xi, J. D. Luketich, S. Raja, W. E. Gooding, V. R. Litle, M. C. Coello, S. D. Finkelstein, M. L. Chestney, R. J. Landreneau, S. J. Hughes, et al. Molecular Staging of Lymph Nodes from Patients with Esophageal Adenocarcinoma Clin. Cancer Res., February 1, 2005; 11(3): 1099 - 1109. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y. Choi, H.-J. Jang, Y. M. Shim, K. Kim, K. S. Lee, K.-H. Lee, Y. Choi, Y. S. Choe, and B.-T. Kim 18F-FDG PET in Patients with Esophageal Squamous Cell Carcinoma Undergoing Curative Surgery: Prognostic Implications J. Nucl. Med., November 1, 2004; 45(11): 1843 - 1850. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. DeMeester Lymph node involvement in esophageal adenocarcinoma: if you see one, have you seen them all? J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 947 - 949. [Full Text] [PDF] |
||||
![]() |
Y. C. Yoon, K. S. Lee, Y. M. Shim, B.-T. Kim, K. Kim, and T. S. Kim Metastasis to Regional Lymph Nodes in Patients with Esophageal Squamous Cell Carcinoma: CT versus FDG PET for Presurgical Detection— Prospective Study Radiology, June 1, 2003; 227(3): 764 - 770. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. W. Rusch Should the esophageal cancer staging system be revised? J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 992 - 993. [Full Text] [PDF] |
||||
![]() |
T. W. Rice, E. H. Blackstone, L. A. Rybicki, D. J. Adelstein, S. C. Murthy, M. M. DeCamp, and J. R. Goldblum Refining esophageal cancer staging J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1103 - 1113. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Hagen and T. R. DeMeester Esophageal adenocarcinoma Ann. Thorac. Surg., October 1, 2001; 72(4): 1430 - 1432. [Full Text] [PDF] |
||||
![]() |
S P L Dexter, H Sue-Ling, M J McMahon, P Quirke, N Mapstone, and I G Martin Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer Gut, May 1, 2001; 48(5): 667 - 670. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-P. Hsu, C.-Y. Chen, J.-Y. Hsia, and S.-E. Shai Prediction of prognosis by the extent of lymph node involvement in squamous cell carcinoma of the thoracic esophagus Eur. J. Cardiothorac. Surg., January 1, 2001; 19(1): 10 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. Christie, T. W. Rice, M. M. DeCamp, J. R. Goldblum, D. J. Adelstein, G. Zuccaro Jr, L. A. Rybicki, and E. H. Blackstone M1A/M1B ESOPHAGEAL CARCINOMA: CLINICAL RELEVANCE J. Thorac. Cardiovasc. Surg., November 1, 1999; 118(5): 900 - 907. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Nigro, S. R. DeMeester, J. A. Hagen, T. R. DeMeester, J. H. Peters, M. Kiyabu, G. M. R. Campos, S. Oberg, O. Gastal, P. F. Crookes, et al. NODE STATUS IN TRANSMURAL ESOPHAGEAL ADENOCARCINOMA AND OUTCOME AFTER EN BLOC ESOPHAGECTOMY J. Thorac. Cardiovasc. Surg., May 1, 1999; 117(5): 960 - 968. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Reed Surgical Management of Esophageal Carcinoma Oncologist, April 1, 1999; 4(2): 95 - 105. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |